Similar articles for PMID: 22586334

Year	Number of Results
1987	1
1989	1
1994	2
1997	2
2000	2
2001	3
2002	1
2003	6
2004	6
2005	2
2006	2
2007	2
2008	1
2009	5
2010	9
2011	9
2012	5
2013	4
2014	6
2015	8
2016	4
2017	6
2018	13
2019	10
2020	6
2021	4

1

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial.

Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, Gouaux B. Corey-Bloom J, et al. CMAJ. 2012 Jul 10;184(10):1143-50. doi: 10.1503/cmaj.110837. Epub 2012 May 14. CMAJ. 2012. PMID: 22586334 Free PMC article. Clinical Trial.

2

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study.

Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M. Vaney C, et al. Mult Scler. 2004 Aug;10(4):417-24. doi: 10.1191/1352458504ms1048oa. Mult Scler. 2004. PMID: 15327040 Clinical Trial.

3

[Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy].

Amato L, Minozzi S, Mitrova Z, Parmelli E, Saulle R, Cruciani F, Vecchi S, Davoli M. Amato L, et al. Epidemiol Prev. 2017 Sep-Dec;41(5-6):279-293. doi: 10.19191/EP17.5-6.AD01.069. Epidemiol Prev. 2017. PMID: 29119763 Free article. Review. Italian.

4

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A; UK MS Research Group. Zajicek J, et al. Lancet. 2003 Nov 8;362(9395):1517-26. doi: 10.1016/S0140-6736(03)14738-1. Lancet. 2003. PMID: 14615106 Clinical Trial.

5

Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial.

Cutter NC, Scott DD, Johnson JC, Whiteneck G. Cutter NC, et al. Arch Phys Med Rehabil. 2000 Feb;81(2):164-9. doi: 10.1016/s0003-9993(00)90135-7. Arch Phys Med Rehabil. 2000. PMID: 10668769 Clinical Trial.

6

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms.

Wade DT, Robson P, House H, Makela P, Aram J. Wade DT, et al. Clin Rehabil. 2003 Feb;17(1):21-9. doi: 10.1191/0269215503cr581oa. Clin Rehabil. 2003. PMID: 12617376 Clinical Trial.

7

Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients.

Wade DT, Makela P, Robson P, House H, Bateman C. Wade DT, et al. Mult Scler. 2004 Aug;10(4):434-41. doi: 10.1191/1352458504ms1082oa. Mult Scler. 2004. PMID: 15327042 Clinical Trial.

8

BoTULS: a multicentre randomised controlled trial to evaluate the clinical effectiveness and cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type A.

Shaw L, Rodgers H, Price C, van Wijck F, Shackley P, Steen N, Barnes M, Ford G, Graham L; BoTULS investigators. Shaw L, et al. Health Technol Assess. 2010 May;14(26):1-113, iii-iv. doi: 10.3310/hta14260. Health Technol Assess. 2010. PMID: 20515600 Free article. Clinical Trial.

9

Patterns of cannabis use among patients with multiple sclerosis.

Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Clark AJ, et al. Neurology. 2004 Jun 8;62(11):2098-100. doi: 10.1212/01.wnl.0000127707.07621.72. Neurology. 2004. PMID: 15184623

10

Do cannabinoids reduce multiple sclerosis-related spasticity?

Thaera GM, Wellik KE, Carter JL, Demaerschalk BM, Wingerchuk DM. Thaera GM, et al. Neurologist. 2009 Nov;15(6):369-71. doi: 10.1097/NRL.0b013e3181bf5572. Neurologist. 2009. PMID: 19901724

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed